Daily Cardiology Research Analysis
Analyzed 310 papers and selected 3 impactful papers.
Summary
Three impactful studies span mechanistic, environmental, and translational cardiology. A mechanistic paper identifies farnesyltransferase (FNTB) loss in cardiomyocytes as a driver of senescence and fibrosis with rescue by AAV9-Fntb, while another randomized crossover human trial links low-level nocturnal road traffic noise to acute endothelial dysfunction with proteomic immune signatures and partial reversal by vitamin C. An AI-enabled CCTA study shows vessel-specific CT-FFR and quantitative plaque features predict nonculprit events post-PCI.
Research Themes
- Cardiac fibrosis and cellular senescence mechanisms under metabolic stress
- Environmental noise as a modifiable cardiovascular risk via endothelial dysfunction
- AI-enabled coronary CT for prognosticating nonculprit vessel events
Selected Articles
1. A randomized, double-blind, crossover study of acute low-level night-time road traffic noise: effects on vascular function, sleep, and proteomic signatures in healthy adults.
In a double-blind, randomized crossover study of 74 healthy adults, low-level nocturnal road traffic noise (LAeq ~41–44 dB; peaks ~60 dB) acutely reduced endothelial function (FMD −1.16% to −1.63%), increased heart rate responses, and impaired subjective sleep. Vitamin C partially restored FMD at higher noise exposure, and proteomics highlighted interleukin signaling and chemotaxis pathways among responders.
Impact: This rigorous human crossover RCT provides mechanistic and clinically relevant evidence that even modest night-time noise acutely impairs endothelial function via oxidative/immune pathways, strengthening the causal chain between environmental noise and cardiovascular risk.
Clinical Implications: Supports public health policies and urban planning to reduce night-time noise exposure; clinicians should counsel vulnerable patients (e.g., hypertension, vascular disease) on sleep environment optimization and consider antioxidant strategies in research settings.
Key Findings
- Nocturnal road traffic noise (30 vs 60 events; LAeq ~41–44 dB) reduced FMD by 1.16% and 1.63%, respectively.
- Vitamin C acutely improved FMD after 60 events (Δ ≈ +1.02%), implicating oxidative stress.
- Noise increased heart rate metrics and odds of post-noise HR peaks (OR 2.42), and worsened subjective sleep quality.
- Targeted proteomics in responders showed changes in interleukin signaling and chemotaxis pathways.
Methodological Strengths
- Randomized, double-blind, crossover design minimizing confounding.
- Multimodal endpoints (FMD, HR metrics, sleep questionnaires, targeted proteomics) with mechanistic probe (vitamin C).
Limitations
- Short-term, acute exposure; no long-term cardiovascular outcomes.
- Healthy volunteer sample may limit generalizability to patients with comorbidities.
Future Directions: Evaluate chronic/intermittent noise mitigation strategies on vascular endpoints in at-risk populations; integrate wearable noise/sleep metrics with omics to identify susceptible phenotypes and test antioxidant/anti-inflammatory interventions.
AIMS: Road traffic noise is the dominant source of environmental noise in Europe and a recognized cardiovascular risk factor, yet direct mechanistic evidence from human studies remains limited. This study investigated the acute effects of low-level night-time road traffic noise exposure on cardiovascular parameters in healthy adults. METHODS AND RESULTS: In a randomized, double-blind, crossover design, 74 healthy participants were exposed to three overnight conditions: control (no noise, average sound pressure level (LAeq) 30.70 dB), 30 (LAeq 41.36), and 60 (LAeq 44.13) recorded road traffic noise events (peak level ≈60 dB). The primary endpoint was endothelial function assessed by flow-mediated dilation (FMD) the morning after each night; a subgroup received vitamin C to assess oxidative stress involvement. Secondary endpoints included sleep quality (questionnaires), cardiovascular parameters (blood pressure, heart rate, electrocardiogram), and targeted proteomic analysis (Olink panels). FMD significantly decreased from 9.35% (control) to 8.19% after 30 noise events (Δ = 1.16%, P = 0.005) and 7.73% after 60 events (Δ = 1.63%, P < 0.0001), with the strongest FMD improvement by vitamin C in the 60-event condition (Δ = 1.02%). Noise exposure increased heart rate (mean difference Δ = 1.23 bpm, P = 0.04; max Δ = 7.95 bpm, P < 0.001) and the odds of post-noise heart rate peaks (odds ratio 2.42, 95% confidence interval 2.07-2.83). After noise exposure, self-reported sleep quality and restfulness were significantly impaired across all dimensions. Clinical chemistry blood parameters did not change significantly. Proteomic analysis revealed noise-associated changes in interleukin signalling and chemotaxis in participants with the strongest FMD impairments. CONCLUSION: Acute exposure to night-time road traffic noise leads to measurable changes in cardiovascular health parameters in healthy adults. These effects were linked to activation of molecular pathways of immune signalling. Plasma proteome changes were correlated to FMD changes (responders vs. non-responders), highlighting interindividual biological susceptibility to noise.
2. Farnesyltransferase Deficiency in Cardiomyocytes Initiates Senescence and Contributes to Cardiac Fibrosis.
Cardiomyocyte-specific Fntb deletion triggered lamin A maturation defects, nuclear envelope instability, DNA damage response activation, and a senescence program that secreted profibrotic signals (TGF-β2, GDF15), driving cardiac fibroblast activation and fibrosis before hypertrophy. Lipid overload downregulated Fntb via SREBF2; AAV9-Fntb overexpression attenuated fibrosis in high-fat diet mice and FNTB was reduced in hyperlipidemic human hearts.
Impact: Uncovers a novel nuclear lamina–senescence axis linking metabolic stress to cardiac fibrosis and demonstrates reversibility via gene therapy, nominating farnesylation/FNTB as a therapeutic target in metabolic heart disease.
Clinical Implications: Suggests screening metabolic heart disease for reduced FNTB expression and exploring farnesylation-pathway modulators or gene therapy (e.g., AAV-mediated FNTB) to prevent or reverse fibrotic remodeling.
Key Findings
- Cardiomyocyte-specific Fntb knockout caused progressive cardiac fibrosis preceding hypertrophy and heightened pressure-overload vulnerability.
- Loss of FNTB impaired lamin A maturation, destabilized the nuclear envelope, activated DNA damage response, and induced cardiomyocyte senescence with increased TGF-β2 and GDF15 secretion.
- Lipid overload downregulated Fntb via SREBF2; AAV9-mediated Fntb overexpression attenuated fibrosis in high-fat diet mice; FNTB was reduced in hyperlipidemic human hearts.
Methodological Strengths
- Multi-tiered mechanistic approach (conditional knockout, ultrastructure, RNA-seq, senescence assays, paracrine signaling).
- Bidirectional validation with human hyperlipidemic heart samples and therapeutic rescue via AAV9-Fntb.
Limitations
- Predominantly preclinical with limited direct clinical translation.
- Long-term safety and feasibility of FNTB-targeted therapies in large animals/humans not addressed.
Future Directions: Assess pharmacologic modulation of farnesylation (e.g., farnesyl donors or pathway activators) and AAV-FNTB in large animal models; map FNTB expression across human cardiometabolic phenotypes and test senolytic co-therapies.
Cardiomyocyte senescence contributes to cardiac fibrosis, yet the molecular mechanisms remain unclear. Farnesylation is a post-translational modification critical for cholesterol metabolism and is mediated by the farnesyltransferase beta subunit (FNTB). However, its specific role in cardiomyocyte senescence and cardiac fibrosis remains unclear. Cardiomyocyte-specific Fntb knockout mice were generated to assess cardiac remodeling. RNA sequencing, DNA damage assays, and senescence markers identified molecular pathways. Mechanistic studies included nuclear envelope ultrastructure analysis, laminA assessments. Clinical relevance was assessed via human heart samples from hyperlipidemic patients. In cardiomyocyte-specific Fntb knockout mice, deletion of FNTB induced progressive cardiac fibrosis that preceded hypertrophy development. Pressure overload exacerbated dysfunction in knockouts, revealing fibrosis-dependent vulnerability. Mechanistically, loss of FNTB impaired laminA maturation, destabilized nuclear envelope integrity, and triggered DNA damage response activation, resulting in cardiomyocyte senescence. Senescent cardiomyocytes secreted elevated Tgf-β2 and Gdf15, driving cardiac fibroblast activation. Upstream regulation studies revealed that lipid overload suppressed Fntb transcription via Srebf2 downregulation, recapitulated in hyperlipidemic human hearts showing reduced FNTB expression. Notably, AAV9-mediated Fntb overexpression attenuated cardiac fibrosis in mice fed a high-fat diet. Collectively, our results demonstra that lipid overload suppresses FNTB expression in cardiomyocytes. This deficiency compromises nuclear integrity, triggering a senescence program and driving cardiac fibrosis. These findings uncover a novel mechanism of lipotoxic cardiomyopathy and suggest that farnesylation warrants further investigation as a potential target to fibrotic remodeling in metabolic heart diseases.
3. AI-enabled Quantitative High-Risk Plaque Attributes for Predicting Coronary Events in Nonculprit Vessels.
In 1,495 PCI patients (2,014 nonculprit vessels; median follow-up 3.3 years), AI-derived CCTA metrics—particularly vessel-specific CT-FFR along with plaque burden and adverse morphology—independently predicted nonculprit vessel MACE (5% event rate). Higher pericoronary adipose tissue attenuation and high-risk plaque features added prognostic information beyond stenosis severity.
Impact: Demonstrates that AI-enabled CCTA can risk stratify nonculprit vessels post-PCI using functional and morphologic signatures, supporting proactive surveillance and tailored secondary prevention.
Clinical Implications: Encourages incorporation of AI-derived CT-FFR, plaque burden, and perivascular fat metrics into post-PCI risk assessments to guide intensification of lipid-lowering, anti-inflammatory therapy, and targeted follow-up imaging.
Key Findings
- Among 2,014 nonculprit vessels, MACE occurred in 5.0% over 3.3 years.
- Vessel-specific CT-FFR was independently associated with lower risk (adjusted HR ~0.14), indicating strong functional prognostication.
- High-risk plaque morphology, higher plaque volume, and elevated pericoronary adipose tissue attenuation added predictive value beyond stenosis.
Methodological Strengths
- Large cohort with vessel-level analysis and multivariable Cox modeling.
- Integration of functional (CT-FFR) and morphologic AI-derived features.
Limitations
- Retrospective single-center design may introduce selection bias and limit generalizability.
- Incomplete abstract limits detailed reporting of all adjusted predictors and performance metrics.
Future Directions: Prospective multicenter validation with decision-impact and cost-effectiveness analyses; randomized trials testing AI-CCTA–guided intensification of secondary prevention in high-risk nonculprit vessels.
Purpose To assess the prognostic value of artificial intelligence (AI)-derived high-risk features obtained from coronary CT angiography (CCTA) in nonculprit vessels of patients who have undergone percutaneous coronary intervention. Materials and Methods This retrospective study included patients who underwent CCTA at a tertiary hospital between June 2013 and June 2023 followed by percutaneous coronary intervention within 3 months. AI-derived high-risk CCTA features were evaluated, including significant stenosis, high-risk plaque, high plaque volume, low CT fractional flow reserve, and high pericoronary adipose tissue attenuation. The primary end point was nonculprit vessel-related major adverse cardiac events (MACE). The prognostic value of high-risk CCTA features was assessed using multivariable Cox regression analyses. Results A total of 1495 patients (mean age, 66 years ± 10; 1100 male patients) with 2014 nonculprit vessels were analyzed with a median follow-up of 3.3 years. MACE occurred in 100 vessels (5.0%). In a multivariable Cox analysis adjusted for high-risk features, vessel-specific CT fractional flow reserve (adjusted hazard ratio, 0.14; 95% CI: 0.03, 0.76;